-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DzthPWaFtIqNB/bJMuv4Y+N8yA/8yu3YcJn1qQdkAkXar+C+oSvAzbXlchxaix6U ltJTSpR5nUs669LpJ0s+Yw== 0001144204-05-004242.txt : 20050214 0001144204-05-004242.hdr.sgml : 20050214 20050211184914 ACCESSION NUMBER: 0001144204-05-004242 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20050214 DATE AS OF CHANGE: 20050211 GROUP MEMBERS: MDS CAPITAL MANAGEMENT CORP. GROUP MEMBERS: MDS CAPITAL USA (GP) INC. GROUP MEMBERS: MDS LIFE SCIENCES TECHNOLOGY BARBADOS INVESTMENT TRUST GROUP MEMBERS: MDS LIFE SCIENCES TECHNOLOGY FUND (GP) INC. GROUP MEMBERS: MDS LIFE SCIENCES TECHNOLOGY FUND LIMITED PARTNERSHIP GROUP MEMBERS: MDS LIFE SCIENCES TECHNOLOGY FUND USA, L.P. GROUP MEMBERS: SC (GP) INC. GROUP MEMBERS: SC BIOTECHNOLOGY DEVELOPMENT FUND LP SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNICON CORP CENTRAL INDEX KEY: 0001083132 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-80333 FILM NUMBER: 05601101 BUSINESS ADDRESS: STREET 1: 3401 MASONS MILL RD STREET 2: SUITE 100 CITY: HUNTINGTON VALLEY STATE: PA ZIP: 19006 BUSINESS PHONE: 215 830 0777 X121 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: MDS CAPITAL CORP CENTRAL INDEX KEY: 0001229595 IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FILING VALUES: FORM TYPE: SC 13G MAIL ADDRESS: STREET 1: MDS CAPITAL CORP STREET 2: 100 INTERNATIONAL BLVD CITY: TORONTO ONTARIO CANADA M9W 6J6 STATE: A6 ZIP: 0000 SC 13G 1 v012552_sc13-g.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ____)* Immunicon Corporation - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, $.001 Par Value Per Share - -------------------------------------------------------------------------------- (Title of Class of Securities) 45260A107 -------------- (CUSIP Number) December 31, 2004 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |_| Rule 13d-1(b) |_| Rule 13d-1(c) |X| Rule 13d-1(d) - ---------- *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). - ------------------- ------------------ CUSIP No. 45260A107 13G Page 1 of 17 Pages - ------------------- ------------------ - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) MDS Capital Corp. - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Ontario, Canada - ------------ ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 1,243,977 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 0 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 1,243,977 - ------------ ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,243,977 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.39% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO - ------------ ------------------------------------------------------------------- - ------------------- ------------------ CUSIP No. 45260A107 13G Page 2 of 17 Pages - ------------------- ------------------ - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) MDS Life Sciences Technology Fund Limited Partnership - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Ontario, Canada - ------------ ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 830,860 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 0 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 830,860 - ------------ ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 830,860 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 3.6% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN - ------------ ------------------------------------------------------------------- - ------------------- ------------------ CUSIP No. 45260A107 13G Page 3 of 17 Pages - ------------------- ------------------ - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) MDS Life Sciences Technology Fund USA, L.P. - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware, USA - ------------ ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 196,450 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 0 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 196,450 - ------------ ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 196,450 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.85% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN - ------------ ------------------------------------------------------------------- - ------------------- ------------------ CUSIP No. 45260A107 13G Page 4 of 17 Pages - ------------------- ------------------ - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) MDS Life Sciences Technology Barbados Investment Trust - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Barbados - ------------ --------- --------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 144,189 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 0 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 144,189 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 0 - ------------ ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 144,189 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.62% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO - ------------ ------------------------------------------------------------------- - ------------------- ------------------ CUSIP No. 45260A107 13G Page 5 of 17 Pages - ------------------- ------------------ - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) SC Biotechnology Development Fund LP - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands - ------------ ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 216,667 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 0 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 216,667 - ------------ ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 216,667 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.93% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN - ------------ ------------------------------------------------------------------- - ------------------- ------------------ CUSIP No. 45260A107 13G Page 6 of 17 Pages - ------------------- ------------------ - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) MDS Life Sciences Technology Fund (GP) Inc. - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Ontario, Canada - ------------ ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 830,860 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 0 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 830,860 - ------------ ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 830,860 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 3.6% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO - ------------ ------------------------------------------------------------------- - ------------------- ------------------ CUSIP No. 45260A107 13G Page 7 of 17 Pages - ------------------- ------------------ - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) MDS Capital USA (GP) Inc. - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware, USA - ------------ ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 196,450 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 0 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 196,450 - ------------ ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 196,450 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.85% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO - ------------ ------------------------------------------------------------------- - ------------------- ------------------ CUSIP No. 45260A107 13G Page 8 of 17 Pages - ------------------- ------------------ - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) SC (GP) Inc. - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands - ------------ ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 216,667 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 0 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 216,667 - ------------ ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 216,667 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.93% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO - ------------ ------------------------------------------------------------------- - ------------------- ------------------ CUSIP No. 45260A107 13G Page 9 of 17 Pages - ------------------- ------------------ - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) MDS Capital Management Corp. - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Ontario, Canada - ------------ ------------------------------------------------------------------- - ------------ ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 830,860 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 0 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 830,860 - ------------ ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 830,860 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 3.6% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO - ------------ ------------------------------------------------------------------- - ------------------- ------------------- CUSIP No. 45260A107 13G Page 10 of 17 Pages - ------------------- ------------------- Item 1(a). Name of Issuer Immunicon Corporation Item 1(b). Address of Issuer's Principal Executive Offices 3401 Masons Mill Road, Suite 100 Huntingdon Valley, Pennsylvania 19006 Item 2(a). Name of Person Filing This statement is filed by: (i) MDS Capital Corp. with respect to shares of common stock $.001 par value per share ("Shares") of the Issuer beneficially owned by MDS Life Sciences Technology Fund Limited Partnership, MDS Life Sciences Technology Fund USA, L.P., SC Biotechnology Development Fund L.P., MDS Life Sciences Technology Fund (GP) Inc., MDS Capital USA (GP) Inc., and SC (GP) Inc.; (ii) MDS Life Sciences Technology Fund Limited Partnership, an Ontario limited partnership, with respect to Shares beneficially owned by it; (iii) MDS Life Sciences Technology Fund USA, L.P., a Delaware limited partnership, with respect to Shares beneficially owned by it; (iv) MDS Life Sciences Technology Barbados Investment Trust, a Barbados trust, with respect to Shares beneficially owned by it; (v) SC Biotechnology Development Fund LP, a Cayman Islands limited partnership, with respect to Shares beneficially owned by it; (vi) MDS Life Sciences Technology Fund (GP) Inc., an Ontario corporation, with respect to Shares beneficially owned by MDS Life Sciences Technology Fund Limited Partnership of which it is general partner; (vii) MDS Capital USA (GP) Inc., a Delaware corporation, with respect to Shares beneficially owned by MDS Life Sciences Technology Fund USA, L.P. of which it is general partner; (viii) SC (GP) Inc., a Cayman Islands corporation, with respect to Shares beneficially owned by SC Biotechnology Development Fund LP of which it is general partner; and (ix) MDS Capital Management Corp., an Ontario corporation, with respect to Shares beneficially owned by MDS Life Sciences Technology Fund Limited Partnership. MDS Life Sciences Technology Fund (GP) Inc., MDS Capital USA (GP) Inc., SC (GP) Inc. and MDS Capital Management Corp. are wholly owned subsidiaries of MDS Capital Corp. As a result of certain relationships, each of the Reporting Persons may be deemed to directly and/or indirectly beneficially own up to 1,388,166 Shares, representing in the aggregate approximately 6% of the outstanding Shares, based on the number of Shares reported to be outstanding as of November 8, 2004 in the Issuer's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2004. Each Reporting Person disclaims beneficial ownership of any securities beneficially owned by any other Reporting Person. - ------------------- ------------------- CUSIP No. 45260A107 13G Page 11 of 17 Pages - ------------------- ------------------- Due to their relationships with one another, the Reporting Persons may be deemed to constitute a "group" under Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Act"), with respect to their beneficial ownership of the Shares. The Reporting Persons, however, expressly disclaim such status and declare that the filing of this Schedule 13G is not and should not be deemed an admission that any Reporting Person, for purposes of Section 13(d) of the Act or otherwise, is the beneficial owner of the Shares held by any other Reporting Person. Item 2(b). Address of Principal Business Office or, if none, Residence The address of the principal office of (i) MDS Capital Corp. is 100 International Boulevard, Toronto, Ontario M9W 6J6; (ii) MDS Life Sciences Technology Fund Limited Partnership is 100 International Boulevard, Toronto, Ontario M9W 6J6; (iii) MDS Life Sciences Technology Fund USA, L.P. is 621 Rose Street, Lincoln, Nebraska 68502; (iv) MDS Life Sciences Technology Barbados Investment Trust is P.O. Box 1371, The Courtyard, Hastings, Christ Church, Barbados; (v) SC Biotechnology Development Fund LP is P.O. Box 1787 GT, Grand Cayman, Cayman Islands; (vi) MDS Capital Management Corp. is 100 International Boulevard, Toronto, Ontario M9W 6J6; (vii) MDS Life Sciences Technology Fund (GP) Inc. is 100 International Boulevard, Toronto, Ontario M9W 6J6; (viii) MDS Capital USA (GP) Inc. is 621 Rose Street, Lincoln, Nebraska 68502; and (ix) SC (GP) Inc. is P.O. Box 1787 GT, Grand Cayman, Cayman Islands. Item 2(c). Citizenship MDS Life Sciences Technology Fund Limited Partnership is an Ontario limited partnership. MDS Life Sciences Technology Fund USA, L.P. is a Delaware limited partnership. SC Biotechnology Development Fund LP is a Cayman Islands limited partnership. MDS Capital Corp., MDS Capital Management Corp., and MDS Life Sciences Technology Fund (GP) Inc. are Ontario corporations. MDS Capital USA (GP) Inc. is a Delaware corporation. SC (GP) Inc. is a Cayman Islands corporation. Item 2(d). Title of Class of Securities Common Stock, $.001 Par Value per Share - ------------------- ------------------- CUSIP No. 45260A107 13G Page 12 of 17 Pages - ------------------- ------------------- Item 2(e). CUSIP Number 45260A107 Item 3. Not applicable Item 4. Ownership As of the close of business on the date of this filing: 1. MDS Capital Corp. (a) Amount Beneficially Owned: 1,243,977 (b) Percent of Class: 5.39% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 1,243,977 (iii) Sole power to dispose or direct the disposition: 0 (iv) Shared power to dispose or direct the disposition: 1,243,977 2. MDS Life Sciences Technology Fund Limited Partnership (a) Amount Beneficially Owned: 830,860 (b) Percent of Class: 3.6% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 830,860 (iii) Sole power to dispose or direct the disposition: 0 (iv) Shared power to dispose or direct the disposition: 830,860 3. MDS Life Sciences Technology Fund USA, L.P. (a) Amount Beneficially Owned: 196,450 (b) Percent of Class: 0.85% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 196,450 (iii) Sole power to dispose or direct the disposition: 0 (iv) Shared power to dispose or direct the disposition: 196,450 4. MDS Life Sciences Technology Barbados Investment Trust (a) Amount Beneficially Owned: 144,189 (b) Percent of Class: 0.62% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 144,189 (ii) Shared power to vote or direct the vote: 0 (iii) Sole power to dispose or direct the disposition: 144,189 (iv) Shared power to dispose or direct the disposition: 0 5. SC Biotechnology Development Fund LP (a) Amount Beneficially Owned: 216,667 (b) Percent of Class: 0.93% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 216,667 (iii) Sole power to dispose or direct the disposition: 0 (iv) Shared power to dispose or direct the disposition: 216,667 - ------------------- ------------------- CUSIP No. 45260A107 13G Page 13 of 17 Pages - ------------------- ------------------- 6. MDS Capital Management Corp. (a) Amount Beneficially Owned: 830,860 (b) Percent of Class: 3.6% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 830,860 (iii) Sole power to dispose or direct the disposition: 0 (iv) Shared power to dispose or direct the disposition: 830,860 7. MDS Life Sciences Technology Fund (GP) Inc. (a) Amount Beneficially Owned: 830,860 (b) Percent of Class: 3.6% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 830,860 (iii) Sole power to dispose or direct the disposition: 0 (iv) Shared power to dispose or direct the disposition: 830,860 8. MDS Capital USA (GP) Inc. (a) Amount Beneficially Owned: 196,450 (b) Percent of Class: 0.85% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 196,450 (iii) Sole power to dispose or direct the disposition: 0 (iv) Shared power to dispose or direct the disposition: 196,450 9. SC (GP) Inc. (a) Amount Beneficially Owned: 216,667 (b) Percent of Class: 0.93% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 216,667 (iii) Sole power to dispose or direct the disposition: 0 (iv) Shared power to dispose or direct the disposition: 216,667 Each of the above Reporting Persons disclaims beneficial ownership of any securities beneficially owned by any other Reporting Person and disclaims that they are a "group" under Section 13(d) of the Act. Item 5. Ownership of Five Percent or Less of a Class Not applicable Item 6. Ownership of More than Five Percent on Behalf of Another Person Not applicable - ------------------- ------------------- CUSIP No. 45260A107 13G Page 14 of 17 Pages - ------------------- ------------------- Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company Not applicable Item 8. Identification and Classification of Members of the Group Not applicable Item 9. Notice of Dissolution of Group Not applicable Item 10. Certifications (a) Not applicable (b) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. - ------------------- ------------------- CUSIP No. 45260A107 13G Page 15 of 17 Pages - ------------------- ------------------- SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct as of February 8, 2005. MDS Capital Corp. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Chief Operating Officer Title: Vice-President - Legal and Secretary MDS Life Sciences Technology Fund Limited Partnership By: MDS Life Sciences Technology Fund (GP) Inc. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President Title: Secretary MDS Life Sciences Technology Fund USA, L.P. By: MDS Capital USA (GP) Inc. By: /s/ Gregory Gubitz By: /s/ Michael Mueller ---------------------------- ----------------------- Name: Gregory Gubitz Name: Michael Mueller Title: Vice-President Title: President - ------------------- ------------------- CUSIP No. 45260A107 13G Page 16 of 17 Pages - ------------------- ------------------- MDS Life Sciences Technology Barbados Investment Trust Per:/s/ Gillian Jordan ---------------------------- Name: Gillian Jordan Title: Trustee SC Biotechnology Development Fund LP By: SC (GP) Inc., its General Partner By: /s/ John Ackerley By: /s/ William Walmsely ---------------------------- ----------------------- Name: John Ackerley Name: William Walmsley Title: Directors of Cardinal Title: Director of Cardinal Investments Limited Investments Limited (Director of SC (Director of SC (GP) Inc.) (GP) Inc.) MDS Life Sciences Technology Fund (GP) Inc. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President Title: Secretary MDS Capital USA (GP) Inc. By: /s/ Gregory Gubitz By: /s/ Michael Mueller ---------------------------- ----------------------- Name: Gregory Gubitz Name: Michael Mueller Title: Vice-President Title: President SC (GP) Inc. By: /s/ John Ackerley By: /s/ William Walmsely ---------------------------- ----------------------- Name: John Ackerley Name: William Walmsley Title: Directors of Cardinal Title: Director of Cardinal Investments Limited Investments Limited (Director of SC (Director of SC (GP) Inc.) (GP) Inc.) - ------------------- ------------------- CUSIP No. 45260A107 13G Page 17 of 17 Pages - ------------------- ------------------- MDS Capital Management Corp. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Chief Operating Officer Title: Vice-President - Legal and Secretary EX-1 2 v012552_ex-1.txt Exhibit 1 Joint Filing Agreement This will confirm the agreement as of February 8, 2005 by and among all the undersigned that the Statement on Schedule 13G filed on or about this date and any further amendments thereto with respect to beneficial ownership by the undersigned of the shares of the common stock, $.001 par value per share, of Immunicon Corporation, a Delaware corporation, is being filed on behalf of each of the undersigned in accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934. The undersigned further agree that each party hereto is responsible for timely filing of such Statement on Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein, provided that no party is responsible for the completeness and accuracy of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate. The undersigned further agree that this agreement shall be included as an Exhibit to such joint filing. This agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. MDS Capital Corp. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Chief Operating Officer Title: Vice-President - Legal and Secretary -2- MDS Life Sciences Technology Fund Limited Partnership By: MDS Life Sciences Technology Fund (GP) Inc. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President Title: Secretary MDS Life Sciences Technology Fund USA, L.P. By: MDS Capital USA (GP) Inc. By: /s/ Gregory Gubitz By: /s/ Michael Mueller ---------------------------- ----------------------- Name: Gregory Gubitz Name: Michael Mueller Title: Vice-President Title: President -3- MDS Life Sciences Technology Barbados Investment Trust By: By: /s/ Gillian Jordan ---------------------------- Name: Gillian Jordan Title: Trustee SC Biotechnology Development Fund LP By: SC (GP) Inc., its General Partner By: /s/ John Ackerley By: /s/ William Walmsely ---------------------------- ----------------------- Name: John Ackerley Name: William Walmsley Title: Directors of Cardinal Title: Director of Cardinal Investments Limited Investments Limited (Director of SC (Director of SC (GP) Inc.) (GP) Inc.) MDS Life Sciences Technology Fund (GP) Inc. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President Title: Secretary -4- MDS Capital USA (GP) Inc. By: /s/ Gregory Gubitz By: /s/ Michael Mueller ---------------------------- ----------------------- Name: Gregory Gubitz Name: Michael Mueller Title: Vice-President Title: President SC (GP) Inc. By: /s/ John Ackerley By: /s/ William Walmsely ---------------------------- ----------------------- Name: John Ackerley Name: William Walmsley Title: Directors of Cardinal Title: Director of Cardinal Investments Limited Investments Limited (Director of SC (Director of SC (GP) Inc.) (GP) Inc.) MDS Capital Management Corp. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Chief Operating Officer Title: Vice-President - Legal and Secretary EX-2 3 v012552_ex-2.txt Exhibit 2 Power of Attorney Know all by these presents, that each of the undersigned hereby constitutes and appoints each of Gregory Gubitz and Graysanne Bedell, signing singly and not jointly, as the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as a beneficial owner of common stock of Immunicon Corporation (the "Issuer"), the Statement on Schedule 13G and any amendments thereto, in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Statement on Schedule 13G and any amendments thereto and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grant to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledge that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Issuer assuming, any of the undersigned's responsibilities to comply with Section 13 of the Securities Exchange Act of 1934 as amended. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Amendments to the Statement on Schedule 13G with respect to the undersigned's holdings of and transactions in securities issued by the Issuer, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. * * * -2- IN WITNESS WHEREOF, each of the undersigned has caused this Power of Attorney to be executed as of this 8th day of February, 2005. MDS Capital Corp. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Chief Operating Officer Title: Vice-President - Legal and Secretary MDS Life Sciences Technology Fund Limited Partnership By: MDS Life Sciences Technology Fund (GP) Inc. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President Title: Secretary MDS Life Sciences Technology Fund USA, L.P. By: MDS Capital USA (GP) Inc. By: /s/ Gregory Gubitz By: /s/ Michael Mueller ---------------------------- ----------------------- Name: Gregory Gubitz Name: Michael Mueller Title: Vice-President Title: President -3- MDS Life Sciences Technology Barbados Investment Trust By: /s/ Gillian Jordan ---------------------------- Name: Gillian Jordan Title: Trustee SC Biotechnology Development Fund LP By: SC (GP) Inc., its General Partner By: /s/ John Ackerley By: /s/ William Walmsely ---------------------------- ----------------------- Name: John Ackerley Name: William Walmsley Title: Directors of Cardinal Title: Director of Cardinal Investments Limited Investments Limited (Director of SC (Director of SC (GP) Inc.) (GP) Inc.) MDS Life Sciences Technology Fund (GP) Inc. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President Title: Secretary -4- MDS Capital USA (GP) Inc. By: /s/ Gregory Gubitz By: /s/ Michael Mueller ---------------------------- ----------------------- Name: Gregory Gubitz Name: Michael Mueller Title: Vice-President Title: President SC (GP) Inc. By: /s/ John Ackerley By: /s/ William Walmsely ---------------------------- ----------------------- Name: John Ackerley Name: William Walmsley Title: Directors of Cardinal Title: Director of Cardinal Investments Limited Investments Limited (Director of SC (Director of SC (GP) Inc.) (GP) Inc.) MDS Capital Management Corp. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Chief Operating Officer Title: Vice-President - Legal and Secretary -----END PRIVACY-ENHANCED MESSAGE-----